Who's buying consumer
brands in 2026, mapped
by buyer.

If you're building a consumer brand and wondering who would actually buy it, the honest first answer is that it depends entirely on which kind of buyer you're built for. The same brand can be worth 3x revenue to one acquirer and 6x to another, because they underwrite completely different things. So the useful way to read the 2026 M&A market isn't deal by deal. It's buyer by buyer.

This post is that map. It's organized by acquirer, split into the three camps of institutional investors and strategic acquirers that price you differently: the CPG and beauty strategics, the private equity and platform sponsors, and the holdcos, aggregators, and brand-management firms. Under each named buyer, you get the 2026 consumer-brand deals they actually did, with the price and multiple where it was disclosed. It's the companion to the deal-by-deal view of the 2026 consumer M&A window, turned inside out to look at the buyers instead of the targets. The full table sits directly below.

The three camps, and
the biggest checks
each one wrote.

The 2026 buyer pool splits into three camps, and the split matters because each one values a brand on a different basis. Strategics (operating companies buying a competitor or an adjacency) price on revenue and pay the top of the range, because they can underwrite synergies a financial model can't see. Private equity and platform sponsors underwrite cash flow and a return, so they anchor on EBITDA and usually pay less for the identical brand. Holdcos, aggregators, and brand-management firms buy the trademark and license out the operating work, so they price the name's licensing income, not the business.

Here's the fast orientation before the detailed tables. These are the largest or most instructive disclosed 2026 deals, one per major buyer, so you can see the shape of who's active and how big they go. The rest of the post fills in each camp.

Read that table and a pattern jumps out. The billion-dollar checks come almost entirely from strategics and one or two large sponsors, and they cluster in beauty, household, and consumer health, the categories with the margin profile to justify a premium. The holdcos are writing big checks too, but for a different thing entirely: they're buying names like Lee, Guess, and Marc Jacobs to license, not brands to operate. That distinction runs through the whole map, and it's the first thing a founder should locate themselves against.

One framing to carry through the rest of the post. A strategic is buying growth or a portfolio gap it can't build fast enough on its own. A sponsor is buying a cash-generating asset it can improve and resell. A holdco is buying a trademark it can monetize through licensing with almost no operating risk. Those are three different questions about your brand, and your job before a sale is to know which question you're the best answer to. That's the same discipline behind what holding companies get wrong when they acquire DTC brands: buyer and brand have to actually match.

The CPG majors buying
proven, profitable
cash flow.

The consumer packaged goods majors were the most disciplined buyers of 2026, and their deals share a signature: proven, profitable, scaled assets bought at low-double-digit EBITDA multiples. Clorox set the tone with the year's largest household deal, agreeing on January 22, 2026 to buy GOJO Industries, the maker of Purell, for $2.25 billion (about $1.92 billion net of an anticipated $330 million tax benefit), funded largely with debt, on a business doing close to $800 million in sales. That's a household-hygiene platform bought for the durability of its cash flow, not a momentum story.

Prestige Consumer Healthcare ran the same playbook in consumer health. It agreed on March 20, 2026 (closing June 15) to buy the Breathe Right nasal-strip portfolio for $1.045 billion, roughly $900 million net of a tax benefit, on a business doing about $200 million in revenue and roughly $95 million of EBITDA at a 47% margin. That's about 5.2x sales and 11x EBITDA for a category-leading, high-margin OTC asset. A brand that profitable and that dominant is exactly the kind a consumer-health strategic will pay up for, because the cash flow is defensible through any ownership change.

Church & Dwight, the Arm & Hammer parent, showed how the majors also fish in distressed waters. On May 29, 2026 it bought Miss Mouth's Messy Eater, the number-one stain remover on Amazon, for about $325 million, roughly 4.1x sales and 11.6x EBITDA on around $80 million of net sales at a 35% EBITDA margin. The seller was the bankrupt Thrasio estate, which is its own signal: the aggregator model that overpaid for Amazon brands in the prior cycle is now feeding proven winners to the strategics at real multiples.

Unilever and P&G stayed in the wellness lane. Unilever agreed in April to buy Gruns, a gummy-multivitamin brand running at roughly $300 million and under three years old, in a deal Forbes and Inc pegged near $1.2 billion (Unilever did not disclose the price). P&G picked up modern OTC-wellness brand Wonderbelly in January. Both fit the pattern: legacy CPG buying a younger, faster-growing consumer-health brand it couldn't build organically, and paying for scale it can plug into a giant distribution machine.

The operator takeaway from this camp is specific. If a CPG major is your likeliest buyer, your EBITDA and your margin durability matter far more than your growth-curve narrative, because these buyers run the brand through a large, unforgiving P&L and price the cash it throws off. That's the same EBITDA line that makes a brand sellable in the first place, and it's the number these acquirers rebuild from scratch in diligence.

The beauty houses buying
prestige, growth, and
global runway.

Beauty produced the single largest consumer deal of 2026 and the most active strategic buyer in the category. L'Oreal completed its acquisition of Kering Beaute, including the House of Creed, for about 4 billion euros (roughly $4.6 billion) on March 31, 2026, its largest deal ever, which also secured 50-year licenses for Bottega Veneta and Balenciaga fragrance and beauty. That was on top of L'Oreal's reported roughly $1 billion move on professional-haircare brand Color Wow in January and a majority stake in Indian DTC house of brands Innovist (Bare Anatomy, Chemist at Play) at a reported $350 million to $450 million valuation. One buyer, three portfolio gaps: luxury fragrance, professional hair, and an India beachhead.

Henkel was the other big beauty buyer, agreeing on March 26, 2026 to take Olaplex private for about $1.4 billion ($2.06 per share, a roughly 55% premium). Per CNBC and Olaplex's own filing, that valued the brand at about 3.3x its $423 million 2025 sales and 13.7x EBITDA. The instructive part is who was on the other side: Olaplex's majority owner, private-equity firm Advent International, was the seller. It's a clean illustration of the map in motion, a sponsor exiting to a strategic, and a reminder that today's PE buyer is often the setup for tomorrow's strategic sale.

Estee Lauder moved from a 49% stake to full ownership of luxury Ayurvedic brand Forest Essentials in March, another India play. Reliance Retail, on the buyer side rather than the target side for once, picked up Priyanka Chopra co-founded clean-haircare brand Anomaly from Maesa. The theme across beauty in 2026 is global runway: the strategics are paying for prestige, for professional channels, and above all for brands with a credible path into India and other high-growth markets they don't yet own.

For a beauty founder, this camp is the one that produces the headline multiples, and it does so for a reason. A beauty house can underwrite a fragrance or clinical-skincare brand at a premium because it already owns the distribution, the counters, and the marketing machine to scale it. If you're not a portfolio fit for one of them, though, the premium evaporates and you fall back to the financial-buyer math. The detailed version of that beauty-specific pricing lives in who's buying beauty brands and at what multiple.

The food and beverage
strategics, where the
volume really is.

Food and beverage was the deepest deal pool of 2026 by a wide margin, and the buyers were mostly established strategics adding growth brands to legacy portfolios. Danone was among the most active, buying meal-replacement leader Huel for $1.15 billion (about 3.4x FY25 sales, and placed under UK CMA review), then agreeing in July to acquire Australia's Made Group for a reported $1.4 billion to push into high-protein foods in Asia-Pacific. Danone is buying the two consumer trends that actually move volume right now: functional nutrition and protein.

The spirits and beverage strategics were unusually busy. E. & J. Gallo bought Four Roses bourbon from Kirin for $715 million plus a $50 million earn-out, a rich 5.96x sales that shows what a scarce, aged-inventory spirits brand commands. Mark Anthony Group (the White Claw parent) added ready-to-drink brand The Finnish Long Drink for $325 million. Molson Coors made its first spirits-based RTD acquisition through Monaco Cocktails, Constellation Brands took full control of non-alcoholic functional brand HOPWTR, and Bacardi bought out the remaining founder stake in Teeling Whiskey. The through-line: beverage majors are buying into ready-to-drink, no-and-low-alcohol, and functional formats where the growth actually is.

In packaged food, the deals ran more conservatively. Smithfield Foods bought Nathan's Famous for $450 million (2.9x sales, 12.4x EBITDA), The Marzetti Company paid $400 million for Japanese BBQ-sauce brand Bachan's (about 4.6x projected sales), and B&G Foods picked up the College Inn and Kitchen Basics broth brands from Del Monte for $110 million at 5.5x adjusted EBITDA. Nestle bought out the founders of German meal-replacement brand yfood Labs. The multiples tell the story: a scarce spirits brand clears 6x sales, while a mature broth business changes hands near 5x EBITDA. Category and durability set the number more than the sector label does.

Private equity, the
buyer that sets the
floor not the ceiling.

Private equity and platform sponsors were active across 2026, mostly at the smaller and mid end, and they price differently from strategics on purpose. This is the camp people mean by institutional investors acquiring consumer brands: firms deploying fund capital against a target return rather than an operating strategy. A financial buyer underwrites your free cash flow and that return, which structurally caps what it will pay for growth it can't be sure continues. The result is usually a lower revenue multiple than a strategic would offer for the identical brand, but often a better partner for a founder who wants to take chips off the table and keep building. The clearest 2026 example of PE reach is Bain Capital buying Japanese personal-care platform FineToday from CVC for $1.29 billion, about 1.87x FY24 sales.

Advent International was on both sides of the map in 2026, which is worth pausing on. It sold Olaplex to Henkel and, in March, took a majority stake in premium body-care and fragrance brand Salt & Stone, a top deodorant at Sephora and Amazon running roughly $165 million in 2025 revenue. That's the PE flywheel in one firm: exit a mature asset to a strategic, redeploy into a fast-growing one. I broke that specific deal down in the broader 2026 acquisitions roundup, and it's a textbook version of how sponsors build the next thing a strategic will want.

Bridgepoint agreed to buy derm-skincare and aesthetics brand Obagi Medical for up to $460 million as Waldencast refocused on Milk Makeup. L Catterton took majority control of cottage-cheese brand Good Culture (reported around $500 million) and a minority position in Paris fragrance house Ex Nihilo. Bansk Group bought wellness-shot leader So Good So You, Boyne Capital took majority control of YZY Fragrances, and ACON Investments took control of organic-candy brand YumEarth (reported near $75 million in revenue and $9 million of EBITDA). Notice how many of these are majority-but-not-all deals: the sponsor takes control, the founder rolls equity and keeps building, and everyone underwrites a bigger second exit.

The practical read on this camp is that its lower headline multiple is not automatically a worse outcome. A good sponsor brings operating discipline, a second bite through rollover equity, and often a path to the strategic premium later. The way you win with a financial buyer is preparation, not narrative: clean accrual books, documented contribution margin by channel, honest add-backs, and funded working capital. The cleaner the data room, the less risk they price in, and the higher the number they can defend to their investment committee. It's the same reason a private-equity roll-up of celebrity DTC brands lives or dies on the underlying unit economics, not the famous name on the label.

Holdcos and aggregators,
buying the name, not
the business.

The third camp buys something the other two don't: the trademark itself. Brand-management holdcos acquire a name, license the operating rights to a third party, and collect royalty income with almost no inventory or operating risk. Authentic Brands Group is the archetype, and it was busy in 2026, acquiring the Lee denim IP from Kontoor for $750 million upfront plus a $250 million earn-out (up to $1 billion), taking majority control of Guess IP at $16.75 per share (the Marciano family kept 49%), and picking up the Care Bears IP. ABG doesn't want to run a denim factory. It wants the Lee trademark and a licensee to operate it.

WHP Global ran the same model, buying Marc Jacobs from LVMH (with G-III as operating partner) and taking a 50% controlling stake in Lands' End for $300 million in cash through a joint venture. Marquee Brands took majority control of Roberto Cavalli. The apparel and fashion names moving in 2026 were largely trademark transactions, not operating-company sales, which is a completely different kind of exit for a founder: you're selling the name's licensing potential, and the operating team usually goes to a licensee rather than the acquirer. If your brand's value is mostly in the mark, this is your camp, and the trade-offs are the ones I walk through in the operate-versus-license decision for brand houses.

The aggregators and platform roll-ups round out this camp. Yellow Wood Partners merged Suave and Elida Beauty into a roughly $1.9 billion retail-sales personal-care platform called Evermark. New holdco Kindred Brands made its first acquisition (skincare brand Kinship) with a stated ambition to build an Honest Company-style platform. Skyline Beauty Group added LilyAna Naturals as its sixth Amazon-heavy skincare brand. Trek One Capital bought Good Karma and No Cow in a same-day plant-based double, and Havenly Brands extended its home roll-up with The Expert. These are platforms buying add-ons to justify their own scale, which means a well-run sub-scale brand has more potential homes in 2026 than it did a couple of years ago.

One caution about this camp. The aggregator model that dominated 2020 to 2022, Amazon roll-ups buying anything with a review count, largely broke, and Thrasio's bankruptcy (whose estate sold Miss Mouth's to Church & Dwight) is the tombstone. The platforms still buying in 2026 are more disciplined and more operator-led than that cohort was. If a roll-up is courting you, the question to ask is whether they're buying your brand because it fits a real operating thesis, or because they need deal volume to service their own debt. The answer changes everything about the outcome.

What the disclosed
multiples actually
tell you.

Most 2026 consumer deals didn't disclose a multiple, but the ones that did draw a clear map of where value sits. The cleanest pattern is on EBITDA: household, consumer-health, and packaged-food deals clustered tightly around 11x to 12x EBITDA, regardless of buyer. Clorox and GOJO landed near 11.9x, Nathan's Famous at 12.4x, Edgewell's feminine-care unit at 12.1x, Church & Dwight's Miss Mouth's at 11.6x, and Breathe Right around 11x. That band is the real anchor for a profitable, scaled consumer brand in 2026, not the flashy revenue multiples from beauty.

The revenue multiples spread far wider, and the spread is the whole point. On the low end, distressed or low-margin assets changed hands below or near 1x sales: Betterware bought Tupperware's Latin American business at 0.90x sales, and Allbirds sold to American Exchange Group for $39 million in a plainly distressed deal. In the middle, scaled profitable brands ran 2x to 4x sales. At the top, scarce or high-margin brands cleared 5x and up: Breathe Right at 5.2x, Four Roses at 5.96x. Revenue multiple isn't a category constant. It's a proxy for margin, growth, and scarcity, which is why the same "sold for a big number" headline can mean radically different things.

Two structural reminders sit underneath these numbers. First, disclosed multiples skew high, because the deals big and clean enough to publish a multiple are the better ones. The quiet, undisclosed transactions that make up most of the deal-log almost certainly ran lower. Second, upfront value and total value differ. Gallo's Four Roses number includes a $50 million earn-out; ABG's Lee deal is $750 million upfront with $250 million contingent. A large share of a celebrated headline is often money the seller has to go earn after the close, which is a very different outcome than cash at signing.

If you want the category-by-category cut of these numbers, with the medians and the ranges rather than one flagship deal per buyer, that's the sister reference to this one: consumer brand acquisition multiples by category for 2026. This post tells you who's buying; that one tells you what they paid per dollar of revenue and profit across food, beauty, apparel, and wellness.

Why the same brand
gets three different
numbers.

Look at the mechanism that makes the buyer matter more than the brand. Take a hypothetical $30 million brand at 12% EBITDA, and hand it to each camp. A strategic that needs your category might pay 4x to 5x revenue ($120 million to $150 million) because it can fold you into distribution it already owns and underwrite synergies. A financial sponsor underwriting your $3.6 million of EBITDA at 8x to 10x pays $29 million to $36 million. A holdco valuing your trademark's licensing income pays something else entirely, tied to royalty potential, not the operating P&L. Same brand, three prices, and the gap between them is enormous.

This is why "engineer the brand for the buyer" isn't a slogan. A brand built for a strategic acquisition needs a growth curve and a category position worth owning. A brand built for a PE exit needs clean, defensible cash flow and a fundable margin. A brand built to be licensed needs broad awareness and a mark that stretches across product categories. Trying to be all three at once usually means being compelling to none of them, and the founders who clear the best numbers pick a lane early and build the brand their most likely buyer actually wants.

The failure mode I saw most often on the buy side was a mismatch between the story and the math. A founder tells a growth story, expecting a revenue multiple, to a financial buyer who is quietly running EBITDA math the entire time. The moment diligence starts, the mismatch surfaces, the buyer rebuilds the number on their basis, and the price resets downward. You don't lose the deal on the low number. You lose it on the surprise, because now the buyer questions everything else you told them.

There's a timing dimension too. Strategics don't buy on a steady cadence, they buy in waves, driven by where their own portfolio is weak, what the last earnings call promised, and how much dry powder they have after a divestiture. When Coty flagged a review of its roughly $1.2 billion Consumer Beauty division, or Nestle moved to shed its ice-cream business, that's not just a seller appearing, it's a buyer freeing up capital to chase the growth it actually wants. Reading those signals tells you when your category's window is open, and a process run into a hungry strategic clears a meaningfully higher number than the same brand sold into a quiet stretch.

How to use the map
if you're building
toward a sale.

If a sale is on your horizon, the acquirer map is a planning tool, not just a scoreboard. The work sequences over roughly 12 to 18 months, and it's the same work that builds a better business whether or not you ever sell. Start by identifying your camp honestly, then build the specific thing that camp underwrites, then run a process wide enough to create competitive tension. Here's how that tends to sequence.

The single most common mistake I see is anchoring on a headline. A founder reads that a brand in their category sold for a big multiple and assumes that's their number, without checking whether the buyer in that deal is a plausible buyer for them, or whether the target had a margin and growth profile they can't match. The multiple attaches to the brand-and-buyer pair, not to the category. Anchor on the wrong pair and you've set an expectation the market will never meet, and you'll read every real offer as an insult.

The optimistic version of this map is that there are more buyers, and more kinds of buyers, than most founders realize. A brand too small for L'Oreal can be exactly right for a sponsor building a platform, or a name a holdco wants to license, or an add-on for an aggregator that needs scale. The strategic premium is real but narrow. The broader opportunity is matching your brand to the buyer whose model it actually fits, and building deliberately toward that buyer for a couple of years before you ever pick up the phone. For a grounded reality check on what these outcomes look like for a typical founder, not the headline outliers, the realistic DTC exit at $3.25M is the honest companion to this map.

How to read this map
as the year keeps
moving.

This is a living reference, updated monthly at a minimum and more often as new deal intel lands, sometimes several times a day. It was last updated July 9, 2026. More than 100 consumer-brand acquisitions were logged in the first six months of the year alone, with food and beverage and beauty producing the deepest deal flow. The named buyers here are the active ones as of July 2026, but the roster matters less than the pattern behind it. Watch which camp a given brand attracts, and you'll understand what that brand is really worth.

I've been on the buy side of this. At WIN Brands Group we operated consumer brands and we acquired them, which meant running the quality-of-earnings work that takes a founder's numbers apart and deciding what our own capital would pay. That experience is why I keep coming back to one point: founders anchor on a headline number from a deal they read about, without checking whether the buyer in that deal is even a plausible buyer for their brand. The buyer is the variable that matters most, and it's the one people study least.

A note on the data behind this map, and the sourcing hierarchy. Primary sources are the origin for every public-company deal: SEC filings (the 8-K, 6-K, and proxy materials the buyer or seller files), company investor-relations releases, and the regulatory bodies that clear or review a deal (the SEC and FTC in the US, the UK CMA, the EU Commission). Trade press (Retail Dive, Beauty Independent, BeautyMatter, WWD, Business of Fashion, BevNET) is the secondary layer, useful for context and for the private deals that never touch a filing, and cross-checked against Drew Fallon's "Making Cents" deal tracker for the smaller transactions. The primary source for each major public-company transaction is linked directly in the table below. Where an amount was reported rather than officially disclosed, I say so. Implied multiples are approximations, because enterprise value and revenue timing are rarely published cleanly. Treat this as the shape of the market, updated for 2026, not a quote on your specific brand.

Where the acquirer is private (Bain Capital and FineToday, Advent International and Salt & Stone, L Catterton and Good Culture, Bansk Group, ACON Investments, WHP Global, Marquee Brands, Yellow Wood Partners, and E. & J. Gallo's purchase of Four Roses), there is no acquirer filing to link, so those deals are sourced to the company's own statement and the trade press named above. In several cases the seller is public and its filing is the origin instead: Kirin Holdings for Four Roses, CVC's disclosure for FineToday, and Waldencast for Obagi. When a private deal later produces a filing (a sponsor-owned brand going public, or a strategic reporting it), the primary source gets added here.

A few signals worth tracking as the rest of 2026 plays out. Watch the divestitures, because a major shedding a division (Coty reviewing Consumer Beauty, Nestle selling ice cream, Estee Lauder weeding underperformers) is both a seller and a buyer freeing up capital. Watch the exploratory processes: Fenty Beauty's 50% stake, Saltair, Dr.Jart+, and Purely Elizabeth were all reportedly testing the market mid-year, which tells you where the next wave of deals may land. And watch the sponsors, because a PE firm buying a fast-growing brand today is usually building the asset a strategic pays a premium for in two or three years.

The ownership picture is getting more concentrated and more complex at the same time, which is exactly why a by-buyer map is useful. If you want to trace which parent now sits behind which consumer brand, the companion piece is the 2026 DTC brand ownership map, and the running ledger of completed and pending deals lives in the 2026 consumer brand exits tracker. Together, those three references answer the three questions a founder or an investor actually asks: who's buying, what did they pay, and who owns whom now.

The single idea to carry out of this map is that the buyer is the variable, not the constant. The camp that acquires you (a strategic chasing a portfolio gap, a sponsor underwriting cash flow, or a holdco licensing a name) sets your price more than any single thing about your brand. The 2026 deals prove it: the same profitable consumer brand could clear 12x EBITDA from a CPG major, 8x from a sponsor, or a royalty-based number from a holdco. Knowing which of those buyers you're built for, and building deliberately toward them, is the entire game.

If you're building a consumer brand toward a sale and you want to know which of these camps is your real buyer, and what they'll actually pay, that's exactly the buy-side work I've run, applied to your brand before a buyer applies it to yours. The consumer commerce practice exists for this kind of pre-deal work, and the free DTC growth scorecard is a fast way to see where your brand sits before a buyer scores it for you.

Questions founders ask
about who's buying
right now.

Q: Who is buying consumer brands in 2026?

Q: Which private equity firms are acquiring consumer brands in 2026?

Q: What are the biggest consumer brand acquisitions of 2026?

Q: What multiples are consumer brands selling for in 2026?

Q: What is the difference between a strategic and a financial buyer for a consumer brand?